Web Date: July 17, 2012
Human Genome Sciences Bows To GlaxoSmithKline’s $3 Billion Bid
Human Genome Sciences has agreed to be purchased by GlaxoSmithKline in a transaction valued at about $3 billion. The decision marks HGS’s failure to attract a higher bid after it rejected a $2.6 billion overture by the British drug firm in April. After turning down that initial bid by GSK, HGS hired Goldman Sachs and Credit Suisse to explore options.
Under the agreement, GSK will attain full ownership of . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society